Can We Eliminate Opioid Medications for Postoperative Pain Control? A Prospective, Surgeon-Blinded, Randomized Controlled Trial in Knee Arthroscopic Surgery.

このレポートは 本レポートは によって検証されています。

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Ninety-five patients who underwent knee arthroscopy surgery with partial meniscal debridement randomized to receive post-surgery prescription of a prescription sent directly to the pharmacy for oxycodone (5 mg of 20 tablets), or given an optional physical copy of the prescription (oxycodone 5 mg of 20 tablets) with instructions to pick up only if necessary. All patients received a multimodal analgesia protocol of 325 mg Aspirin (2x/day for 28 days), 500 mg naproxen (2x/day for 28 days), and 1000 mg Acetaminophen (3x/day for 7 days). The primary outcome of interest was the total number of Oxycodone tablets used post-surgery. Secondary outcomes of interest were number of days opioids were taken post-surgery, pain measured on a Visual Analogue Scale (VAS), and the incidence of adverse events. In addition, other outcomes measured were the length of operation, and number of tablets taken and remaining. All variables were measured at 21 days post-surgery, except for VAS pain which was was measured at 2 hours, 24 hours, 48 hours, 7 days, and 21 days follow-up. The results revealed no statistically significant differences between the 2 groups in all outcomes except for the total number of tablets taken, which was lower in the electronic prescription group vs physical prescription group (169 vs. 211; p<0.001). Furthermore, the mean number of tablets remaining per patient (16.5+/-5.3 vs. 13.8+/-7.2; p=0.04) and the total number of tablets remaining (791 vs. 649; p<0.001) were also found statistically significantly higher in the electronic prescription group compared to the physical prescription group.